Biodesix Inc is a diagnostics & research business based in the US. Biodesix shares (BDSX) are listed on the NASDAQ and all prices are listed in US Dollars. Biodesix employs 200 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Active traders
Our top pick for
Beginners
Our top pick for
Building a portfolio
| Latest market close | $4.75 |
|---|---|
| 52-week range | $4.02 - $31.99 |
| 50-day moving average | $5.99 |
| 200-day moving average | $10.57 |
| Wall St. target price | $16.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.36 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.75 from 2022-01-14
| 1 week (2022-01-10) | -16.67% |
|---|---|
| 1 month (2021-12-17) | -1.86% |
| 3 months (2021-10-15) | -36.67% |
| 6 months (2021-07-16) | -58.37% |
| 1 year (2021-01-15) | -83.04% |
|---|---|
| 2 years (2020-01-13) | N/A |
| 3 years (2019-01-13) | N/A |
| 5 years (2017-01-13) | N/A |
| Revenue TTM | $74.3 million |
|---|---|
| Gross profit TTM | $23.6 million |
| Return on assets TTM | -27.86% |
| Return on equity TTM | -1089.34% |
| Profit margin | -46.31% |
| Book value | $0.59 |
| Market capitalisation | $175.5 million |
TTM: trailing 12 months
We're not expecting Biodesix to pay a dividend over the next 12 months.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
